Literature DB >> 27529560

Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).

Kuan-Wei Huang1,2, Kai-Cheng Hsu3, Lee-Ya Chu2,4,5, Jinn-Moon Yang1,6,7, Hanna S Yuan2, Yu-Yuan Hsiao1,6,8.   

Abstract

The DEDDh family of exonucleases plays essential roles in DNA and RNA metabolism in all kingdoms of life. Several viral and human DEDDh exonucleases can serve as antiviral drug targets due to their critical roles in virus replication. Here using RNase T and CRN-4 as the model systems, we identify potential inhibitors for DEDDh exonucleases. We further show that two of the inhibitors, ATA and PV6R, indeed inhibit the exonuclease activity of the viral protein NP exonuclease of Lassa fever virus in vitro. Moreover, we determine the crystal structure of CRN-4 in complex with MES that reveals a unique inhibition mechanism by inducing the general base His179 to shift out of the active site. Our results not only provide the structural basis for the inhibition mechanism but also suggest potential lead inhibitors for the DEDDh exonucleases that may pave the way for designing nuclease inhibitors for biochemical and biomedical applications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27529560     DOI: 10.1021/acs.jmedchem.6b00794

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Nucleoside analogues for the treatment of coronavirus infections.

Authors:  Andrea J Pruijssers; Mark R Denison
Journal:  Curr Opin Virol       Date:  2019-05-21       Impact factor: 7.090

2.  High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.

Authors:  Biswajit Naik; Nidhi Gupta; Rupal Ojha; Satyendra Singh; Vijay Kumar Prajapati; Dhaneswar Prusty
Journal:  Int J Biol Macromol       Date:  2020-05-26       Impact factor: 6.953

3.  Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2.

Authors:  Rangika Munaweera; Ying S Hu
Journal:  Front Chem       Date:  2021-01-21       Impact factor: 5.221

4.  TREX1 as a Novel Immunotherapeutic Target.

Authors:  Wayne O Hemphill; Sean R Simpson; Mingyong Liu; Freddie R Salsbury; Thomas Hollis; Jason M Grayson; Fred W Perrino
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

5.  Targeted Covalent Inhibitors Allosterically Deactivate the DEDDh Lassa Fever Virus NP Exonuclease from Alternative Distal Sites.

Authors:  Kuan-Wei Huang; Jing-Wen Chen; Tzu-Yu Hua; Yu-Yu Chu; Tsai-Yuan Chiu; Jung-Yu Liu; Chun-I Tu; Kai-Cheng Hsu; Ya-Ting Kao; Jhih-Wei Chu; Yu-Yuan Hsiao
Journal:  JACS Au       Date:  2021-11-16

Review 6.  Not making the cut: Techniques to prevent RNA cleavage in structural studies of RNase-RNA complexes.

Authors:  Seth P Jones; Christian Goossen; Sean D Lewis; Annie M Delaney; Michael L Gleghorn
Journal:  J Struct Biol X       Date:  2022-03-11

7.  Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.

Authors:  Sergio Hernández; Mikael Feracci; Carolina Trajano De Jesus; Priscila El Kazzi; Rafik Kaci; Laura Garlatti; Clemence Mondielli; Fabrice Bailly; Philippe Cotelle; Franck Touret; Xavier de Lamballerie; Bruno Coutard; Etienne Decroly; Bruno Canard; François Ferron; Karine Alvarez
Journal:  Antiviral Res       Date:  2022-06-16       Impact factor: 10.103

Review 8.  Progress in Anti-Mammarenavirus Drug Development.

Authors:  Yu-Jin Kim; Victor Venturini; Juan C de la Torre
Journal:  Viruses       Date:  2021-06-22       Impact factor: 5.048

9.  The Antiviral Effect of the Chemical Compounds Targeting DED/EDh Motifs of the Viral Proteins on Lymphocytic Choriomeningitis Virus and SARS-CoV-2.

Authors:  Mya Myat Ngwe Tun; Kouichi Morita; Takeshi Ishikawa; Shuzo Urata
Journal:  Viruses       Date:  2021-06-24       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.